Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes
Conditions
Brief summary
Phase II trial to study the effectiveness of thalidomide in treating patients who have myelodysplastic syndrome. Thalidomide may improve the immune system's ability to fight myelodysplastic syndrome
Detailed description
OBJECTIVES: I. Determine whether thalidomide improves cytopenias in patients with myelodysplastic syndromes. II. Determine the toxicity of this regimen in these patients. III. Determine whether this regimen down regulates the peripheral blood levels of tumor necrosis factor alpha, interferon gamma, and interleukin-12 and whether these changes correlate with clinical response in these patients. IV. Determine whether this regimen alters the peripheral blood T-cell subset distribution and whether these changes correlate with clinical response in these patients. V. Determine the effect of this regimen on bone marrow microvessel density and whether these effects correlate with clinical response in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to prognosis (favorable vs unfavorable). (Favorable stratum closed to accrual 12/28/01) Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 1 year and then annually for 4 years. PROJECTED ACCRUAL: A total of 20-58 patients (10-29 per stratum) will be accrued for this study within 20 months. (Favorable stratum closed to accrual 12/28/01)
Interventions
DRUGthalidomide
Given orally
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pre-transfusion hemoglobin =\< 10 g/dL * Pre-transfusion platelet count =\< 50,000/μL * Absolute neutrophil count \< 1000/μL * Total bilirubin ≤ 1.5 x UNL * Alkaline phosphatase ≤ 3 x UNL * AST ≤ 3 x UNL * Creatinine ≤ 1.5 x UNL * A diagnosis of MDS as demonstrated in the bone marrow; any subtypes are eligible including: * Refractory anemia (cytopenia) * Refractory anemia with ringed sideroblasts * Chronic myelomonocytic leukemia * Refractory anemia with excess blasts * Refractory anemia with excess blasts in transformation * Unclassified MDS * Patients with refractory anemia with excess blasts in transformation who are not candidates for (or who decline) induction chemotherapy are eligible; those patients who were candidates for (and accepted) induction chemotherapy should have failed at least 1 chemotherapy regimen prior to entry * Patients who are candidates for marrow transplantation should have this option discussed prior to study entry
Exclusion criteria
* Any of the following as this regimen may be harmful to a developing fetus or nursing child: * Pregnant women * Nursing women * Women of childbearing potential or their sexual partners who are unwilling to employ 2 adequate methods of contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) * Peripheral neuropathy (by history or clinical exam) * Concomitant therapy ≤ 30 days for myelodysplastic syndrome with any specific agent including chemotherapy, corticosteroids and/or growth factors (i.e. erythropoietin, G-CSF, GM-CSF, thrombopoietic agent); patients on chronic low-dose corticosteriods (\< 20 mg/d) for reasons other than MDS are allowed * Uncontrolled infections
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed response defined as complete hematologic response (CHR) or partial response (PR) or hematological improvement (HI) on 2 consecutive evaluations in terms of proportion of successes measured using criteria reported by Cheson et al | Up to 3 months | Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. |
| Incidence and severity of toxicities, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0 | Up to 5 years | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival time | Time from registration to death due to any cause, assessed up to 5 years | Estimated using the method of Kaplan-Meier. |
| Time to disease progression | Time from registration to documentation of disease progression, assessed up to 5 years | Estimated using the method of Kaplan-Meier. |
| Duration of response measured using criteria reported by Cheson et al | Date at which the patient's objective status is first noted to be either a CHR or PR to the date progression is documented, assessed up to 5 years | — |
| Time to treatment failure | Time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 5 years | — |
Countries
United States
Outcome results
None listed